172 related articles for article (PubMed ID: 37713267)
1. Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
Lauer EM; Riegler E; Mutter JA; Alig SK; Bleul S; Kuehn J; Ranganathan L; Klingler C; Demerath T; Würtemberger U; Rau A; Weiß J; Eisenblaetter M; Bamberg F; Prinz M; Finke J; Duyster J; Illerhaus G; Diehn M; Alizadeh AA; Schorb E; Reinacher PC; Scherer F
Neuro Oncol; 2024 Feb; 26(2):374-386. PubMed ID: 37713267
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter JA; Alig SK; Esfahani MS; Lauer EM; Mitschke J; Kurtz DM; Kühn J; Bleul S; Olsen M; Liu CL; Jin MC; Macaulay CW; Neidert N; Volk T; Eisenblaetter M; Rauer S; Heiland DH; Finke J; Duyster J; Wehrle J; Prinz M; Illerhaus G; Reinacher PC; Schorb E; Diehn M; Alizadeh AA; Scherer F
J Clin Oncol; 2023 Mar; 41(9):1684-1694. PubMed ID: 36542815
[TBL] [Abstract][Full Text] [Related]
3. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Heger JM; Mattlener J; Schneider J; Gödel P; Sieg N; Ullrich F; Lewis R; Bucaciuc-Mracica T; Schwarz RF; Rueß D; Ruge MI; Montesinos-Rongen M; Deckert M; Blau T; Kutsch N; Balke-Want H; Weiss J; Becker K; Reinhardt HC; Hallek M; Borchmann P; von Tresckow B; Borchmann S
Blood; 2024 Feb; 143(6):522-534. PubMed ID: 37946299
[TBL] [Abstract][Full Text] [Related]
4. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.
Tabouret E; Houillier C; Martin-Duverneuil N; Blonski M; Soussain C; Ghesquières H; Houot R; Larrieu D; Soubeyran P; Gressin R; Gyan E; Chinot O; Taillandier L; Choquet S; Alentorn A; Leclercq D; Omuro A; Tanguy ML; Hoang-Xuan K
Neuro Oncol; 2017 Mar; 19(3):422-429. PubMed ID: 27994065
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging patterns in central nervous system lymphomas: A pictorial review.
Voultsinou D; Mantatzis M; Gerukis T; Heva A; Birbilis T; Prassopoulos P
Clin Imaging; 2021 Oct; 78():1-7. PubMed ID: 33706068
[TBL] [Abstract][Full Text] [Related]
7. [
Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of circulating tumor DNA in central nervous system lymphoma.
Foerster AK; Lauer EM; Scherer F
Semin Hematol; 2023 Jul; 60(3):150-156. PubMed ID: 37442670
[TBL] [Abstract][Full Text] [Related]
9. Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.
Wu JJ; Wang WH; Dong M; Ma SS; Zhang XD; Zhu LN; Niu ST; Ding MJ; Zhang JM; Zhang L; Li X; Li L; Sun ZC; Wang XH; Fu XR; Li ZM; Chang Y; Nan FF; Yan JQ; Yu H; Wu XL; Zhou ZY; Zhang MZ
Invest New Drugs; 2022 Jun; 40(3):650-659. PubMed ID: 35137332
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system lymphoma: a morphological MRI study.
Koubska E; Weichet J; Malikova H
Neuro Endocrinol Lett; 2016 Sep; 37(4):318-324. PubMed ID: 27857050
[TBL] [Abstract][Full Text] [Related]
11. New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.
Blasel S; Vorwerk R; Kiyose M; Mittelbronn M; Brunnberg U; Ackermann H; Voss M; Harter PN; Hattingen E
J Neurol; 2018 Mar; 265(3):647-658. PubMed ID: 29383512
[TBL] [Abstract][Full Text] [Related]
12. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
Barajas RF; Politi LS; Anzalone N; Schöder H; Fox CP; Boxerman JL; Kaufmann TJ; Quarles CC; Ellingson BM; Auer D; Andronesi OC; Ferreri AJM; Mrugala MM; Grommes C; Neuwelt EA; Ambady P; Rubenstein JL; Illerhaus G; Nagane M; Batchelor TT; Hu LS
Neuro Oncol; 2021 Jul; 23(7):1056-1071. PubMed ID: 33560416
[TBL] [Abstract][Full Text] [Related]
13. Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Meling TR; Latysheva A; Da Broi M; Jahr G; Holte H; Beiske K; Emblem KE
Neuroradiology; 2018 Jul; 60(7):703-713. PubMed ID: 29804159
[TBL] [Abstract][Full Text] [Related]
14. Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.
Ben Bouallègue F; Tabaa YA; Kafrouni M; Cartron G; Vauchot F; Mariano-Goulart D
Med Phys; 2017 Sep; 44(9):4608-4619. PubMed ID: 28513853
[TBL] [Abstract][Full Text] [Related]
15. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
16. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
18. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
Woff E; Salvatore L; Marmorino F; Genovesi D; Critchi G; Guiot T; Ameye L; Sclafani F; Hendlisz A; Flamen P
J Nucl Med; 2022 Apr; 63(4):549-555. PubMed ID: 34326124
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic and prognostic value of MRI in central nervous system involvement of acute myeloid leukemia: a retrospective cohort of 84 patients.
Shen H; Zhao Y; Shi Y; Sun J; Zhou D; Li L; Ye X; Xie W
Hematology; 2020 Dec; 25(1):258-263. PubMed ID: 32567523
[No Abstract] [Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
